Cargando…
Two years’ experience with denosumab for children with Osteogenesis imperfecta type VI
BACKGROUND: Osteogenesis imperfecta (OI) is a hereditary disease causing reduced bone mass, increased fracture rate, long bone deformities and vertebral compressions. Additional non skeletal findings are caused by impaired collagen function and include hyperlaxity of joints and blue sclera. Most OI...
Autores principales: | Hoyer-Kuhn, Heike, Netzer, Christian, Koerber, Friederike, Schoenau, Eckhard, Semler, Oliver |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4180531/ https://www.ncbi.nlm.nih.gov/pubmed/25257953 http://dx.doi.org/10.1186/s13023-014-0145-1 |
Ejemplares similares
-
Individualized treatment with denosumab in children with osteogenesis imperfecta – follow up of a trial cohort
por: Hoyer-Kuhn, Heike, et al.
Publicado: (2019) -
Personalized medicine in patients with Osteogenesis imperfecta
por: Semler, Oliver, et al.
Publicado: (2014) -
Safety and efficacy of denosumab in children with osteogenesis imperfecta - a first prospective trial
por: Hoyer-Kuhn, H., et al.
Publicado: (2016) -
Osteogenesis imperfecta—pathophysiology and therapeutic options
por: Etich, Julia, et al.
Publicado: (2020) -
Hypercalcemia and hypercalciuria during denosumab treatment in children with osteogenesis imperfecta type VI
por: Trejo, Pamela, et al.
Publicado: (2018)